Accord And Henlius Broaden Trastuzumab Alliance
As Accord Launches Pelgraz Pre-Filled Pegfilgrastim Injector In UK
Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada. Meanwhile, Accord has launched a Pelgraz pegfilgrastim pre-filled injector and patient app in the UK.
You may also be interested in...
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.